Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
Pfizer(PFE) stock is priced at $26.68, giving the company a market capitalization of 151.37B. It carries a P/E multiple of 19.63 and pays a dividend yield of 6.5%.
As of 2026-03-17, Pfizer(PFE) stock has fluctuated between $26.56 and $26.74. The current price stands at $26.68, placing the stock +0.5% above today's low and -0.2% off the high.
Pfizer(PFE) shares are trading with a volume of 109.47K, against a daily average of 39.2M.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.
PFE News
Pfizer (PFE) announced on Tuesday that its investigational breast cancer therapy, atirmociclib, as part of a combination regimen, reached the main goal in a lat...
Pfizer (PFE) announced topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant...
HSBC raised the firm’s price target on Pfizer (PFE) to $32 from $29 and keeps a Buy rating on the shares. The firm says the uncertain macro backdrop, rising geo...
Analyst ratings
55%
of 29 ratingsMore PFE News
Advertisement How Pfizer (PFE) looks after recent performance Pfizer (PFE) shares closed at $26.61, with a 3.5% decline over the past month and a 4.2% return...
Key Points Pfizer’s revenue reached $100 billion a few years ago, driven by its dominance in coronavirus treatments and prevention. In recent times, it’s face...
Pfizer has started new clinical studies tied to its tafamidis and etrasimod franchises, including a Phase 1 tafamidis bioequivalence trial. The company is adva...
China has approved Pfizer's GLP-1 obesity therapy Xianweiying (ecnoglutide), granting the company commercialization rights in mainland China. The therapy was o...
Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Claim 70% Off TipRanks Premium Unlock hedge fund-lev...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. is launching a Phase 2 trial to test how its drug etrasimod works in children...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is launching a Phase 1 study called “A PHASE 1, OPEN-LABEL, RANDOMIZED,...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.